SMPD1 and cancer: The recent revelation that inhibition of ASM with current lysosomal targeting drugs (cationic amphiphiles) shows selective toxicity towards cancer cells and inhibits tumour growth in vivo [158] is both interesting and promising from a therapeutic perspective, supported by the observation that increasing sphingomyelin synthase activity with 2-hydroxyoleic acid has similar anti-cancer efficacy [199].